Consumer Staples · Retail-Drug Stores and Proprietary Stores

GRDN Guardian Pharmacy Services, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 180225580 filings
Russell 2000

GRDN at a glance

Guardian Pharmacy Services, Inc. (GRDN, SEC CIK 1802255) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Guardian Pharmacy Services, Inc. (GRDN) reported revenue of $1.4 billion (up 17.9% from FY2024) and net income of $49.2 million.
  • The most recent insider open-market sale reported on Form 4 was by Martin David Norman on November 17, 2026 of 200 shares at $50.58 per share.
  • In the last 90 days, GRDN insiders reported 0 open-market purchases ($0) and 4 open-market sales ($503K) on Form 4, a net sale of $503K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.4B
+17.9% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$503K
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors since the December 31, 2025 Form 10-K
  • Regulatory risk: existing 10-K risks remain applicable to pharmacy operations
  • Operational risk: carried-forward 10-K risks could adversely affect business and results
  • Financial risk: existing 10-K risks could adversely affect financial condition and prospects
  • Market risk: carried-forward risks could reduce Class A common stock price

Management Discussion & Analysis

  • Q3 revenue $371.1M, down 1.7% from $377.4M, reflecting IRA-related pricing reductions
  • Gross margin 23.0% vs 19.8%; net margin 5.2% vs 2.5% YoY
  • Acquisitions strongest contributor, adding $7.3M revenue; organic revenue decreased $13.7M
  • Cash $119.7M; nine-month operating cash flow $79.5M vs $65.7M, up $13.8M
  • IRA price reductions remain a headwind, expected to affect year-over-year comparability through the remainder of 2026

AI summary of the GRDN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Guardian Pharmacy Services’ financial results for quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed earnings figures and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $371.1M, down 2% YoY despite residents served increasing 7% to approximately 218,000, reflecting IRA pricing pressure
  • Net income $19.1M versus $9.6M, while Adjusted EBITDA rose 24% to $33.9M and margin expanded to 9.1% from 7.2%
Filed Sep 10, 2026Full analysis →

Item 8.01: Other Events

  • Lock-ups cover approximately 29.9 million Class A shares held by founders, executives and employees
  • Restricted shares represent approximately 81% of pre-IPO holders’ approximately 37 million shares
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $351.8M, up 2%; residents served rose 8% to approximately 210,000
  • Adjusted EBITDA $29.7M versus $25.0M; margin expanded to 8.4% from 7.2%

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Guardian Pharmacy Services’ financial results for quarter ended June 30, 2026
  • Investors should review Exhibit 99.1 for revenue, earnings, guidance and operating trends

AI summaries of GRDN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for GRDN

Don't miss the next GRDN filing

  • Alerts as it files. A push when GRDN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GRDN, by share count.
  • Ask anything. An AI agent that reads every GRDN filing and answers with sources.

GRDN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Martin David NormanSellNov 17, 2026$50.58
Martin David NormanSellNov 17, 2026$50.24
Martin David NormanSellNov 17, 2026$50.24
Martin David NormanSellNov 17, 2026$50.58
Ackerman JohnMSep 27, 2026-
Forbes KendallMSep 27, 2026-
Ackerman JohnMSep 27, 2026-
Pharmacy Investors, LLCMSep 27, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$1.2B$1.4B
Gross Profit-$244.4M$292.7M
Operating Income--$62.9M$72.7M
Net Income--$110.0M$49.2M
Gross Margin-19.9%20.2%
Op. Margin--5.1%5.0%
Net Margin--9.0%3.4%
Balance Sheet
Total Assets-$320.8M$412.7M
Equity$59.9M$150.0M$217.9M
ROE--73.4%22.6%
Cash Flow
Operating CF-$58.0M$100.3M

Source: XBRL data in Guardian Pharmacy Services, Inc. (GRDN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

GRDN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 18, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
8-KSep 10, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KJun 22, 2026Analysis-
8-KMay 28, 2026Analysis

Related Consumer Staples companies

All Consumer Staples →

GRDN SEC filings: frequently asked questions

Are GRDN insiders buying or selling?

In the last 90 days, Guardian Pharmacy Services, Inc. (GRDN) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $502,536 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

What was GRDN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Guardian Pharmacy Services, Inc. (GRDN) reported revenue of $1.4 billion (up 17.9% from FY2024) and net income of $49.2 million. The figures come from the XBRL data in the 10-K.

What did GRDN report in its latest 8-K?

Guardian Pharmacy Services, Inc. (GRDN) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Guardian Pharmacy Services’ financial results for quarter ended September 30, 2026.

What are the latest GRDN SEC filings?

Guardian Pharmacy Services, Inc. (GRDN) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 19, 2026.

What is GRDN's SEC CIK number?

Guardian Pharmacy Services, Inc. (GRDN)'s SEC Central Index Key (CIK) is 1802255. EDGAR lists every GRDN filing under that number.

Ask anything about GRDN

The research agent reads GRDN's filings, financials, insider trades and 13F holders, then answers with sources.